Idorsia has kicked off a 12-week Phase 2 proof-of-concept trial of its oral CCR6 antagonist IDOR-1117-2520 in approximately 30 moderate-to-severe psoriasis patients, with topline data due in Q1 2027. A separate Phase 3 analysis showed daridorexant 50 mg improved wake-after-sleep-onset by 43 minutes and total sleep time by 75 minutes in menopausal-aged women.